thought leadership
Are GLP-1s enough to meet growing unmet needs in type 2 diabetes?
By Matt Sauter, Group Creative Director; Phoebe Hobbs, Scientific Business Manager; Catriona Marshall, Manager, Medical Communications and Business Development; Mariam Bibi, Senior Director, Global Real World Evidence; Natasha Cowan, Senior Corporate Communications Manager; Adityavir Nat, Marketing Executive | May 17, 2024
The history of type 2 diabetes treatment is filled with breakthrough innovations that have enhanced disease management for patients. Despite this, there are still areas of unmet need for people with diabetes globally, resulting in inconsistent and inefficient care for patients. We spoke to our experts to explore why glucose-targeting innovations alone will only improve outcomes so much, and what we can do to support this growing patient population.
The industry is at an intersection of life-changing innovation and barriers to care. As this gap widens, transforming patient lives requires more than glucose-targeting treatments. Fueled by a range of factors, access and guidance are driving clinical inertia for type 2 diabetes patients, creating significant areas of unmet need.
Learn how an integrated approach which considers the entire spectrum of patient needs will drive brand leadership, ensure commercial success, and improve patient outcomes.
Download the whitepaper to uncover:
- The current landscape of the type 2 diabetes market
- The drivers behind clinical inertia in type 2 diabetes
- Key areas of unmet patient needs
- Six recommendations for developing a patient-centric approach that drives commercial success.